ArticleBMC infectious diseases2025
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundThis study assessed the real-world effectiveness of the ChAdOx1 nCoV-19 vaccine in adults against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, symptomatic infection, and severe coronavirus disease 2019 (COVID-19) during periods of Beta and Delta variant dominance in Qatar.
methodsA national, matched, test-negative case-control study was conducted using 186,130 PCR-positive tests (cases) and 667,289 PCR-negative tests (controls) collected between January 1 and December 18, 2021. Subgroup analyses were performed to evaluate vaccine effectiveness across key strata.
resultsThe median time between the first and second doses was 61 days (interquartile range, 56-64 days). Two-dose primary-series effectiveness was 66.0% (95% CI, 55.1-74.3%) against any SARS-CoV-2 infection and 73.0% (95% CI, 44.1-87.0%) against symptomatic infection. Effectiveness was estimated at 100% (95% CI, 64.0-100%) against any Beta variant infection and 65.3% (95% CI, 54.2-73.8%) against any Delta infection. Protection against any infection of any variant peaked at 78.4% (95% CI, 50.7-90.5%) within the first month after the second dose, gradually declining to 45.6% (95% CI, 5.5-68.7%) after 150 days. Effectiveness against severe, critical, or fatal COVID-19, irrespective of variant, was 100% (95% CI, 49.3-100%), with no vaccinated individuals progressing to severe, critical, or fatal disease after infection. Effectiveness of a single dose was 59.9% (95% CI, 51.0-67.3%) against any infection-65.0% (95% CI, 49.7-75.6%) against Beta and 55.9% (95% CI, 43.8-65.5%) against Delta-78.4% (95% CI, 60.9-88.0%) against symptomatic infection, and 100% (95% CI, 88.9-100%) against severe, critical, or fatal COVID-19.
conclusionThe ChAdOx1 nCoV-19 vaccine provided substantial protection against infection and strong protection against severe outcomes during periods dominated by the Beta and Delta variants, although protection against infection waned within the first few months following the primary series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.